JP2022525013A5 - - Google Patents
Info
- Publication number
- JP2022525013A5 JP2022525013A5 JP2021552772A JP2021552772A JP2022525013A5 JP 2022525013 A5 JP2022525013 A5 JP 2022525013A5 JP 2021552772 A JP2021552772 A JP 2021552772A JP 2021552772 A JP2021552772 A JP 2021552772A JP 2022525013 A5 JP2022525013 A5 JP 2022525013A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962814316P | 2019-03-06 | 2019-03-06 | |
| US62/814,316 | 2019-03-06 | ||
| PCT/IB2020/051878 WO2020178767A1 (en) | 2019-03-06 | 2020-03-04 | Compounds useful in hiv therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022525013A JP2022525013A (ja) | 2022-05-11 |
| JPWO2020178767A5 JPWO2020178767A5 (https=) | 2024-07-16 |
| JP2022525013A5 true JP2022525013A5 (https=) | 2024-07-16 |
Family
ID=69845479
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021552772A Ceased JP2022525013A (ja) | 2019-03-06 | 2020-03-04 | Ｈｉｖ療法において有用な化合物 |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US12240853B2 (https=) |
| EP (1) | EP3934760A1 (https=) |
| JP (1) | JP2022525013A (https=) |
| KR (1) | KR20210136052A (https=) |
| CN (1) | CN113811360A (https=) |
| AR (1) | AR118240A1 (https=) |
| AU (1) | AU2020231934B2 (https=) |
| BR (1) | BR112021017604A2 (https=) |
| CA (1) | CA3132112A1 (https=) |
| CL (1) | CL2021002309A1 (https=) |
| CO (1) | CO2021012579A2 (https=) |
| CR (1) | CR20210460A (https=) |
| EA (1) | EA202192433A1 (https=) |
| IL (1) | IL285894A (https=) |
| MA (1) | MA55200A (https=) |
| MX (1) | MX2021010700A (https=) |
| PE (1) | PE20212089A1 (https=) |
| PH (1) | PH12021500034A1 (https=) |
| SG (1) | SG11202109253SA (https=) |
| TW (1) | TW202102233A (https=) |
| WO (1) | WO2020178767A1 (https=) |
| ZA (1) | ZA202106096B (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021021717A1 (en) | 2019-07-27 | 2021-02-04 | Brii Biosciences, Inc. | Adenosine derivative and pharmaceutical composition comprising the same |
| PE20221037A1 (es) | 2019-09-11 | 2022-06-17 | Scripps Research Inst | Profarmacos antivirales y composiciones farmaceuticas de los mismos |
| UY38982A (es) | 2019-12-09 | 2021-06-30 | Viiv Healthcare Co | Composiciones farmacéuticas |
| WO2025068743A1 (en) | 2023-09-27 | 2025-04-03 | ViiV Healthcare UK (No.3) Limited | Pharmaceutical composition of cabotegravir |
| US11718637B2 (en) * | 2020-03-20 | 2023-08-08 | Gilead Sciences, Inc. | Prodrugs of 4′-C-substituted-2-halo-2′- deoxyadenosine nucleosides and methods of making and using the same |
| JP2024503755A (ja) * | 2020-12-30 | 2024-01-26 | サウザン・ユニバーシティ・オブ・サイエンス・アンド・テクノロジー | ウイルス感染症治療用ヌクレオシド系化合物及びその用途 |
| CN116710465A (zh) | 2021-01-25 | 2023-09-05 | 腾盛博药生物科技有限公司 | 腺苷衍生物和包含其的药物组合物 |
| TW202237146A (zh) * | 2021-01-25 | 2022-10-01 | 美商布里生物科學股份有限公司 | 使用腺苷衍生物及衣殼抑制劑之hiv組合療法 |
| JP2024507550A (ja) * | 2021-02-23 | 2024-02-20 | ヴィーブ、ヘルスケア、カンパニー | Ｈｉｖ療法に有用な化合物 |
| CN120958007A (zh) * | 2023-01-30 | 2025-11-14 | 默沙东有限责任公司 | 4'-取代核苷逆转录酶抑制剂的前药 |
| CN121909019A (zh) | 2023-09-27 | 2026-04-21 | Viiv保健英国第三有限公司 | 药物组合物 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB427857A (en) | 1934-08-02 | 1935-05-01 | Newsum Sons & Company Ltd H | A new or improved system of construction for skeleton structures, particularly vehicle body frames and door frames |
| US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| ATE250623T1 (de) | 1999-05-12 | 2003-10-15 | Yamasa Corp | 4'-c-ethynyl-purin-nukleoside |
| EP1378509A4 (en) | 2001-03-19 | 2009-03-25 | Ono Pharmaceutical Co | DRUGS WITH TRIAZASPIRO ç5.5] UNDECANDERIVATES AS ACTIVE SUBSTANCE |
| US7037718B2 (en) | 2001-10-26 | 2006-05-02 | Cornell Research Foundation, Inc. | Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof |
| CA2502109C (en) | 2004-03-24 | 2010-02-23 | Yamasa Corporation | 4'-c-substituted-2-haloadenosine derivative |
| CN100532388C (zh) | 2007-07-16 | 2009-08-26 | 郑州大学 | 2’-氟-4’-取代-核苷类似物、其制备方法及应用 |
| US20090318380A1 (en) | 2007-11-20 | 2009-12-24 | Pharmasset, Inc. | 2',4'-substituted nucleosides as antiviral agents |
| US8927513B2 (en) | 2009-07-07 | 2015-01-06 | Alnylam Pharmaceuticals, Inc. | 5′ phosphate mimics |
| US9198972B2 (en) | 2010-01-28 | 2015-12-01 | Alnylam Pharmaceuticals, Inc. | Monomers and oligonucleotides comprising cycloaddition adduct(s) |
| WO2011133871A2 (en) | 2010-04-22 | 2011-10-27 | Alnylam Pharmaceuticals, Inc. | 5'-end derivatives |
| EP2619215B1 (en) | 2010-09-22 | 2018-09-05 | Alios Biopharma, Inc. | Azido nucleosides and nucleotide analogs |
| US9770035B2 (en) | 2011-10-06 | 2017-09-26 | Dow Agrosciences Llc | Nucleic acid molecules that target RPA70 and confer resistance to coleopteran pests |
| AU2013235220C1 (en) | 2011-12-22 | 2019-03-28 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| UA117095C2 (uk) | 2011-12-22 | 2018-06-25 | Аліос Біофарма, Інк. | Нуклеозидна сполука або її фармацевтично прийнятна сіль |
| US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| HK1224229A1 (zh) | 2013-06-26 | 2017-08-18 | Alios Biopharma, Inc. | 取代的核苷，核苷酸及其类似物 |
| EP3055319A4 (en) | 2013-10-11 | 2018-01-10 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| WO2015143712A1 (en) | 2014-03-28 | 2015-10-01 | Merck Sharp & Dohme Corp. | 4'-substituted nucleoside reverse transcriptase inhibitors |
| TN2016000566A1 (en) | 2014-06-24 | 2018-04-04 | Alios Biopharma Inc | Substituted nucleosides, nucleotides and analogs thereof |
| LT3160476T (lt) | 2014-06-24 | 2021-04-12 | Janssen Biopharma, Inc. | Pakeistieji nukleozidai, nukleotidai ir jų analogai, skirti naudoti virusinių infekcijų gydyme |
| WO2016057866A1 (en) | 2014-10-09 | 2016-04-14 | Board Of Regents Of The University Of Nebraska | Compositions and methods for the delivery of therapeutics |
| WO2016066283A1 (en) * | 2014-10-31 | 2016-05-06 | Sandoz Ag | Improved fluorination process |
| MA41213A (fr) | 2014-12-19 | 2017-10-24 | Alios Biopharma Inc | Nucléosides substitués, nucléotides et analogues de ceux-ci |
| CN108289931B (zh) * | 2015-09-23 | 2022-10-11 | 默沙东公司 | 4’-取代的核苷逆转录酶抑制剂及其制备 |
| JOP20170038B1 (ar) | 2016-02-12 | 2021-08-17 | Merck Sharp & Dohme | مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه |
| EP4299133A3 (en) | 2016-06-23 | 2024-03-13 | VIIV Healthcare Company | Compositions and methods for the delivery of therapeutics |
| EP3529254B1 (en) | 2016-11-03 | 2023-02-22 | Laurence I. Wu | Prodrugs of clofarabine |
| US20190185508A1 (en) | 2017-12-15 | 2019-06-20 | Merck Sharp & Dohme Corp. | Deuterated nucleoside reverse transcriptase inhibitors |
| US20200407393A1 (en) * | 2018-03-07 | 2020-12-31 | Glaxosmithkline Intellectual Property (No. 2) Limited | Medical Use |
| WO2019199667A2 (en) | 2018-04-09 | 2019-10-17 | Keaney Gregg F | Certain pladienolide compounds and methods of use |
| WO2020031131A1 (en) | 2018-08-09 | 2020-02-13 | Glaxosmithkline Intellectual Property (No.2) Limited | Compounds useful in hiv therapy |
| JP2021536444A (ja) | 2018-08-30 | 2021-12-27 | グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited | Ｈｉｖ療法に有用な化合物 |
| ES2971482T3 (es) | 2019-03-06 | 2024-06-05 | Greentech Global Pte Ltd | Dispersiones líquidas para haluros de acilo |
-
2020
- 2020-03-04 AU AU2020231934A patent/AU2020231934B2/en not_active Ceased
- 2020-03-04 WO PCT/IB2020/051878 patent/WO2020178767A1/en not_active Ceased
- 2020-03-04 CA CA3132112A patent/CA3132112A1/en active Pending
- 2020-03-04 PH PH1/2021/500034A patent/PH12021500034A1/en unknown
- 2020-03-04 BR BR112021017604A patent/BR112021017604A2/pt not_active IP Right Cessation
- 2020-03-04 EP EP20712038.7A patent/EP3934760A1/en active Pending
- 2020-03-04 CR CR20210460A patent/CR20210460A/es unknown
- 2020-03-04 TW TW109107136A patent/TW202102233A/zh unknown
- 2020-03-04 KR KR1020217031465A patent/KR20210136052A/ko not_active Withdrawn
- 2020-03-04 PE PE2021001461A patent/PE20212089A1/es unknown
- 2020-03-04 CN CN202080030422.7A patent/CN113811360A/zh active Pending
- 2020-03-04 EA EA202192433A patent/EA202192433A1/ru unknown
- 2020-03-04 JP JP2021552772A patent/JP2022525013A/ja not_active Ceased
- 2020-03-04 SG SG11202109253SA patent/SG11202109253SA/en unknown
- 2020-03-04 AR ARP200100588A patent/AR118240A1/es not_active Application Discontinuation
- 2020-03-04 MA MA055200A patent/MA55200A/fr unknown
- 2020-03-04 MX MX2021010700A patent/MX2021010700A/es unknown
- 2020-05-04 US US16/865,678 patent/US12240853B2/en active Active
-
2021
- 2021-06-01 US US17/335,145 patent/US20220411425A1/en not_active Abandoned
- 2021-08-24 ZA ZA2021/06096A patent/ZA202106096B/en unknown
- 2021-08-26 IL IL285894A patent/IL285894A/en unknown
- 2021-09-03 CL CL2021002309A patent/CL2021002309A1/es unknown
- 2021-09-24 CO CONC2021/0012579A patent/CO2021012579A2/es unknown
-
2023
- 2023-11-14 US US18/508,355 patent/US20240182473A1/en not_active Abandoned
-
2025
- 2025-02-12 US US19/051,307 patent/US20260035371A1/en active Pending